Article

A 6-week time period may not be sufficient to identify potential adverse events following COVID-19 vaccination

2022-11-30

Abstract excerpt

<title>Abstract</title> <p>Background . Messenger RNA (mRNA) vaccines have been widely used as the main sanitary measure destined to fight the COVID-19 pandemic. Rapidly purported as being “safe and effective”, this new generation of vaccines is radically different from those developed traditionally and for which potentially associated adverse events (AEs) are considered through a standard 6-week post-vaccinatio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 697efb4d-401b-588f-89d1-445836c742de
DOI: 10.21203/rs.3.rs-2327212/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A 6-week time period may not be sufficient to identify potential adverse events following COVID-19 vaccinationDOI 10.21203/rs.3.rs-2327212/v1Read

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from GreeceSemantic proximity Read

An objective systematic comparison of the most common adverse events of COVID-19 vaccinesSemantic proximity Read

Self-Reported Adverse Events Following SARS-CoV-2 Vaccination: A Nationwide Questionnaire Study in the Adult Danish PopulationSemantic proximity Read

Review on different COVID-19 vaccines approved for Emergency Use Listing by WHO until 11 July 2022: characterization, pharmacological properties, mechanism of action and adverse events.Semantic proximity Read

Serious adverse events reported from the COVID-19 vaccines: A descriptive study based on WHO databaseSemantic proximity Read

Cohort monitoring of 29 Adverse Events of Special Interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sourcesSemantic proximity Read

Contextualizing adverse event following immunization data of coronavirus disease 2019 (COVID-19) vaccines in VigiAccess: An approach for reducing COVID-19 vaccine hesitancySemantic proximity Read

Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent VaccinesSemantic proximity Read

Association between COVID-19 Vaccination and Neuropsychiatric ConditionsSemantic proximity Read

Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity Read

Clinical Features and Vaccine Efficacy Analysis of COVID-19 patients in a Chongqing Shelter hospital in 2022Semantic proximity Read

Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance AnalysisSemantic proximity Read